Wells Fargo Maintains Overweight on BioNTech, Lowers Price Target to $125
Benzinga Newsdesk 3 hours ago
Analyst RatingsNewsPrice Target
Wells Fargo analyst Mohit Bansal maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers the price target from $140 to $125.
Wells Fargo analyst Mohit Bansal maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers the price target from $140 to $125.